Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services

Laureate Pharma, Inc. a US based biopharmaceutical contract manufacturing organization and Selexis SA, a Swiss based contract developer of high performance production cell lines, jointly announced today their continued collaboration via a joint-marketing relationship. This expanded relationship provides streamlined access to a set of highly complementary contract services.

This relationship offers the opportunity to generate highly productive, stable mammalian cells producing gram quantities of recombinant protein materials in as little as eight weeks, post transfection. In parallel, cGMP compliant manufacturing processes can be developed for a streamlined approach for the production of clinical-grade material.

"We are pleased to be working with Selexis and their highly advanced approach to developing high performance production cell lines," said Dr. Robert Broeze, President & CEO of Laureate Pharma. "Combining the Selexis approach to cell line development with our strong track-record of cGMP manufacturing provides a very compelling value proposition for clients looking to outsource biopharmaceutical manufacturing."

"Including Laureate in our network of manufacturing partners is of great benefit to our clients seeking a US based manufacturer with a long history of successful cGMP compliant manufacturing," said Dr. Igor Fisch, President and CEO of Selexis. "Laureate is a leader in this area and we are very pleased to be in association with this strong organization."